Organigram Holdings Inc. (OGI.TO)
| Previous Close | 2.3400 |
| Open | 2.3400 |
| Bid | 2.3200 x N/A |
| Ask | 2.3300 x N/A |
| Day's Range | 2.2950 - 2.3600 |
| 52 Week Range | 1.3500 - 3.9500 |
| Volume | |
| Avg. Volume | 228,790 |
| Market Cap | 251.889M |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Organigram Closes Second Tranche of Previously Announced BAT Private Placement Investment
TORONTO, September 03, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the "Second Tranche") of the previously announced C$124,559,674 follow-on strategic equity investment (the "Investment") by BT DE Investments Inc. (the "Investor"), a wholly owned subsidiary of British American Tobacco plc ("BAT"). Pursuant to the Second T
- Business Wire
Organigram Reports Third Quarter Fiscal 2024 Results
TORONTO, August 13, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024").
- Business Wire
Organigram Product Development Collaboration Completes Landmark Clinical Study on Nanoemulsion Technology
TORONTO, August 07, 2024--Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PDC
